CXCL9 chemokine in ulcerative colitis

被引:30
作者
Elia, G. [1 ]
Guglielmi, G. [2 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Via Savi 10, I-56126 Pisa, Italy
[2] Univ Hosp Pisa, Operat Unit Prevent & Occupat Med, Pisa, Italy
来源
CLINICA TERAPEUTICA | 2018年 / 169卷 / 05期
关键词
CXCR3; CXCL9; ulcerative colitis;
D O I
10.7417/CT.2018.2085
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this narrative review is to highlight the role of CXCL9 in Ulcerative Colitis (UC), in order to understand the mechanism underlying the inflammation in UC and to investigate also if Th1- chemokines could be useful as a marker of disease. It was shown that chemokine (C-X-C motif) receptor (CXCR)3 and its ligand chemokine, monokine induced by interferon (IFN)-gamma(MIG)/chemokine (C-X-C motif) ligand 9 (CXCL)9, are highly overexpressed both in the intestinal mucosa of mice with experimental colitis and in patients with UC (specifically, in lymphocytes, macrophages and epithelial cells). In epithelial colonic cells CXCL9 expression is increased by IFN-gamma. MIG has an important role in the recruitment of mononuclear cells and granulocytes, so in maintaining the inflammation in UC. Since serum CXCL9 levels are related with UC disease activity, it could be a marker for the responsiveness of patients to treatments. It has been recently suggested that blocking CXCL9 may be a potentially effective therapy for moderately-to-severely active UC.
引用
收藏
页码:E235 / E241
页数:7
相关论文
共 118 条
[31]   CXCL9 and CXCL11 Chemokines Modulation by Peroxisome Proliferator-Activated Receptor-α Agonists Secretion in Graves' and Normal Thyrocytes [J].
Antonelli, Alessandro ;
Ferrari, Silvia Martina ;
Frascerra, Silvia ;
Pupilli, Cinzia ;
Mancusi, Caterina ;
Metelli, Maria Rita ;
Orlando, Claudio ;
Ferrannini, Ele ;
Fallahi, Poupak .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (12) :E413-E420
[32]   Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone [J].
Antonelli, Alessandro ;
Ferrari, Silvia Martina ;
Fallahi, Poupak ;
Piaggi, Simona ;
Paolicchi, Aldo ;
Franceschini, Stefano Sellari ;
Salvi, Mario ;
Ferrannini, Ele .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (02) :277-283
[33]   Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: Modulation by peroxisome proliferator-activated receptor-gamma agonists [J].
Antonelli, Alessandro ;
Ferrari, Silvia Martina ;
Fallahi, Poupak ;
Ghiri, Emiliano ;
Crescioli, Clara ;
Romagnani, Paola ;
Vitti, Paolo ;
Serio, Mario ;
Ferrannini, Ele .
CYTOKINE, 2010, 50 (03) :260-267
[34]   Prevalence of thyroid dysfunctions in systemic lupus erythematosus [J].
Antonelli, Alessandro ;
Fallahi, Poupak ;
Mosca, Marta ;
Ferraria, Silvia Martina ;
Ruffilli, Ilaria ;
Corti, Alessandro ;
Panicucci, Erica ;
Neri, Rossella ;
Bombardieri, Stefano .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2010, 59 (06) :896-900
[35]   Dysregulation of secretion of CXC α-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-γ agonists [J].
Antonelli, Alessandro ;
Ferrari, Silvia Martina ;
Fallahi, Poupak ;
Frascerra, Silvia ;
Piaggi, Simona ;
Gelmini, Stefania ;
Lupi, Cristiana ;
Minuto, Michele ;
Berti, Piero ;
Benvenga, Salvatore ;
Basolo, Fulvio ;
Orlando, Claudio ;
Miccoli, Paolo .
ENDOCRINE-RELATED CANCER, 2009, 16 (04) :1299-1311
[36]   Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells [J].
Antonelli, Alessandro ;
Ferrari, Silvia Martina ;
Fallahi, Poupak ;
Berti, Piero ;
Materazzi, Gabriele ;
Minuto, Michele ;
Giannini, Riccardo ;
Marchetti, Ivo ;
Barani, Lucio ;
Basolo, Fulvio ;
Ferrannini, Ele ;
Miccoli, Paolo .
CLINICAL ENDOCRINOLOGY, 2009, 70 (06) :946-953
[37]   Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy [J].
Baschieri, L ;
Antonelli, A ;
Nardi, S ;
Alberti, B ;
Lepri, A ;
Canapicchi, R ;
Fallahi, P .
THYROID, 1997, 7 (04) :579-585
[38]  
Berends SE, 2018, CLIN PHARMACOKINET
[39]   Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis [J].
Bohm, Stephan Karl ;
Kruis, Wolfgang .
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 :369-383
[40]   The Gut Epithelial Receptor LRRC19 Promotes the Recruitment of Immune Cells and Gut Inflammation [J].
Cao, Shuisong ;
Su, Xiaomin ;
Zeng, Benhua ;
Yan, Hui ;
Huang, Yugang ;
Wang, Enlin ;
Yun, Huan ;
Zhang, Yuan ;
Liu, Feifei ;
Li, Wenxia ;
Wei, Hong ;
Che, Yongzhe ;
Yang, Rongcun .
CELL REPORTS, 2016, 14 (04) :695-707